Document Type

Article

Publication Date

4-20-2026

Abstract

Purpose

Postsurgical adhesion remains a significant clinical challenge. Seprafilm® is widely used as a barrier to reduce adhesion formation, however its efficacy may be inconsistent. Recombinant human proteoglycan-4 (rhPRG4), a surface-active, anti-inflammatory glycoprotein found in synovial fluid inhibits cell and protein adhesion. This study investigated whether coating Seprafilm with rhPRG4 could enhance its anti-adhesive potential.

Methods

Macrophages (J774), human fibroblast-like synoviocytes (HFLS), and melanoma (A375) cells were cultured on tissue culture wells treated with rhPRG4 or bovine submaxillary mucin (BSM) to determine optimal seeding density. Seprafilm sheets were coated with rhPRG4 or BSM (0.78–200 µg/mL). Cell adhesion was quantified using CellTiter-Glo® while non-adherent macrophages were assessed for viability and re-adhesion. Migration was tested with the Oris Universal Cell Migration assay and oxidative stress with MitoSOX Red staining. ANOVA with multiple comparisons was used for statistical analysis.

Results

Seprafilm alone promoted HFLS and macrophage adhesion, whereas application of rhPRG4 significantly reduced adherence compared to both control and BSM coated surfaces. The combination of rhPRG4 with Seprafilm showed the greatest reduction in adhesion without compromising viability or re-adherence. Seprafilm alone increased macrophage migration and ROS production, while rhPRG4 coated surfaces alone or in combination with Seprafilm suppressed both.

Conclusion

Coating Seprafilm with rhPRG4 enhances its anti-adhesive properties by reducing adhesion, migration, and oxidative stress in vitro. These findings suggest rhPRG4 may improve the biological performance of adhesion barriers by suppressing early cellular infiltration and inflammatory activation. Anti-adhesive bioactive surface modifications may advance postsurgical adhesion prevention and wound healing.

Comments

This article was originally published in Annals of Biomedical Engineering in 2026. https://doi.org/10.1007/s10439-026-04120-x

10439_2026_4120_MOESM1_ESM.png (788 kB)
Supplementary Information Figure S1 (PNG 789 kb)

10439_2026_4120_MOESM2_ESM.png (1021 kB)
Supplementary Information Figure S2 (PNG 1022 kb)

10439_2026_4120_MOESM3_ESM.jpg (1055 kB)
Supplementary Information Figure S3 (JPG 1056 kb)

10439_2026_4120_MOESM4_ESM.png (163732 kB)
Supplementary Information Figure S4 (PNG 1022 kb)

10439_2026_4120_MOESM5_ESM.png (4485 kB)
Supplementary Information Figure S5 (PNG 4486 kb)

10439_2026_4120_MOESM6_ESM.png (439 kB)
Supplementary Information Figure S6 (PNG 440 kb)

10439_2026_4120_MOESM7_ESM.tif (14643 kB)
Supplementary Information Table S1 (TIF 14644 kb)

10439_2026_4120_MOESM8_ESM.jpg (88 kB)
Supplementary Information Table S2 (JPG 89 kb)

10439_2026_4120_MOESM9_ESM.jpg (107 kB)
Supplementary Information Table S3 (JPG 108 kb)

10439_2026_4120_MOESM10_ESM.png (2969 kB)
Supplementary Information Table S4 (PNG 2970 kb)

10439_2026_4120_MOESM11_ESM.tif (14098 kB)
Supplementary Information Table S5 (TIF 14099 kb)

10439_2026_4120_MOESM12_ESM.png (4566 kB)
Supplementary Information Table S6 (PNG 4567 kb)

10439_2026_4120_MOESM13_ESM.docx (11803 kB)
Supplementary file13 (DOCX 11804 kb)

Copyright

The authors

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.